Probiotic Recolonisation Therapy

Abstract

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.


Claims
IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Aug 22, 2017
  • Application: Feb 5, 2016
    US US 201615017364 A
  • Priority: Feb 5, 2016
    US US 201615017364 A
  • Priority: Jul 7, 2015
    US US 201514793630 A
  • Priority: Jul 7, 2015
    US US 201514793642 A
  • Priority: May 12, 2015
    US US 201514710487 A
  • Priority: May 12, 2015
    US US 201514710481 A
  • Priority: May 5, 2014
    US US 201414270034 A
  • Priority: Jun 5, 2013
    US US 201313910579 A
  • Priority: Jul 25, 2001
    AU AU 2007/001009 W
  • Priority: Jul 25, 2000
    AU AU PQ899700 A

Download Citation


Sign in to the Lens

Feedback